NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 71 resultados LastUpdate Última actualización 14/05/2021 [15:18:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES

NºPublicación: WO2021084500A1 06/05/2021

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: WO2021084500A1

The present invention discloses compounds formula (I): (I) wherein X is CH; The present compounds of formula (I) are dihydroorotate dehydrogenase (DHODH) inhibitors, and are useful for the treatment of inflammatory disorders, autoimmune disorders and cancer, such as e.g. lymphomas, leukemias, carcinomas, and sarcomas. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 60 to 136; examples 1 to 39; tables 1 and 2). An exemplary compound is e.g. : 4-ethyl-1-(7-fluoro-4-isopropyl-2- (2-methoxyphenyl)quinolin-6-yl)-3-(hydroxymethyl)-1H-1,2,4- triazol-5(4H)-one (example 1): (AA)

traducir

BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA

NºPublicación: US2021128618A1 06/05/2021

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: US2021128618A1

Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least two BCMA-binding moieties, a transmembrane domain, and an intracellular signaling domain. The dose of CAR-T cells administered to the subject is from 4.0×105 to 1.0×106 of CAR-T cells per kilogram of the subject's mass. Alternatively, the dose comprises 1×106 to 1×108 of the CAR-T cells.

traducir

METHODS FOR TREATMENT OR PREVENTION OF LEUKEMIA

NºPublicación: US2021128602A1 06/05/2021

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]

WO_2018165482_PA

Resumen de: US2021128602A1

The present disclosure relates generally to methods for preventing, ameliorating or treating leukemia. In particular, the present disclosure relates to administering a therapeutically effective amount of at least one agent to reduce the expression of synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP) to a subject diagnosed with, or at risk for acute myeloid leukemia (AML).

traducir

COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER

NºPublicación: US2021130453A1 06/05/2021

Solicitante:

MEDIMMUNE LTD [GB]
FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL HEBRON [ES]
FUNDACIO PRIVADA INST CATALANA DE RECERCA I ESTUDIS AVANCATS [ES]

CN_112585164_A

Resumen de: US2021130453A1

Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and PD-1 axis inhibitors.

traducir

GENETIC MODIFICATION OF RATS

NºPublicación: US2021130846A1 06/05/2021

Solicitante:

REGENERON PHARMA [US]

MX_2019015525_A

Resumen de: US2021130846A1

Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (ES) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided. Such methods and compositions comprise an in vitro culture comprising a feeder cell layer and a population of rat ES cells or a rat ES cell line, wherein the in vitro culture conditions maintain pluripotency of the ES cell and comprises a media having mouse leukemia inhibitory factor (LIF) or an active variant or fragment thereof. Various methods of establishing such rat ES cell lines are further provided. Methods of selecting genetically modified rat ES cells are also provided, along with various methods to generate a transgenic rat from the genetically modified rat ES cells provided herein. Various kits and articles of manufacture are further provided.

traducir

ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA

NºPublicación: US2021130460A1 06/05/2021

Solicitante:

MORPHOSYS AG [DE]

WO_2021084062_A1

Resumen de: US2021130460A1

The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.

traducir

METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: US2021128557A1 06/05/2021

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]
DANA FARBER CANCER INST INC [US]

Resumen de: US2021128557A1

Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.

traducir

T CELL RECEPTORS FOR IMMUNOTHERAPY

NºPublicación: US2021130431A1 06/05/2021

Solicitante:

UNIV TEXAS [US]

Resumen de: US2021130431A1

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

traducir

ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS

NºPublicación: US2021130461A1 06/05/2021

Solicitante:

MORPHOSYS AG [DE]

WO_2021084063_A1

Resumen de: US2021130461A1

The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.

traducir

Methods of treating peripheral T cell lymphoma using anti-CD30 antibody drug conjugate therapy

NºPublicación: AU2019355875A1 06/05/2021

Solicitante:

SEAGEN INC

Resumen de: AU2019355875A1

The present disclosure, relates, in general to methods treating peripheral T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy.

traducir

Heterocyclic kinase inhibitors and uses thereof

NºPublicación: AU2019368654A1 06/05/2021

Solicitante:

IOMX THERAPEUTICS AG

WO_2020083926_A1

Resumen de: AU2019368654A1

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

traducir

Chimeric antigen receptors targeting B-cell maturation antigen

NºPublicación: AU2021202158A1 06/05/2021

Solicitante:

THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY [US]

US_2021123063_A1

Resumen de: AU2021202158A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF

NºPublicación: AU2021202119A1 06/05/2021

Solicitante:

EPIZYME INC [US]

CN_110420327_A

Resumen de: AU2021202119A1

The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

traducir

FLUORINATED QUINOLINE, QUINOXALINE AND BENZOB1,4OXAZINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES

NºPublicación: WO2021084498A1 06/05/2021

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: WO2021084498A1

The present invention discloses compounds formula (I): (I) wherein X is CH; R2 is (AA) R3 is (BB) The present compounds of formula (I) are dihydroorotate dehydrogenase (DHODH) inhibitors, and are useful for the treatment of inflammatory disorders, autoimmune disorders and cancer, such as e.g. lymphomas, leukemias, carcinomas, and sarcomas. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 61 to 101; examples 1 to 24; tables 1 and 2). An exemplary compound is e.g. 7-(4-ethyl-3-(hydroxymethyl)-5- oxo-4,5-dihydro-1H-1,2,4-triazol-l-yl)-6-fluoro-3-(3-fluorophenyl) -1-isopropylquinolin-4(1H)-one (example 1): (CC)

traducir

INHIBITORS OF MMEJ PATHWAY FOR PREVENTION AND TREATMENT OF PRE-MYELOID AND MYELOID MALIGNANCIES

NºPublicación: WO2021084540A1 06/05/2021

Solicitante:

YEDA RES & DEV [IL]

Resumen de: WO2021084540A1

An inhibitor of a component of the Microhomology Mediated End Joining (MMEJ) pathway is provided for use in treating or prevention of a pre-myeloid or myeloid malignancy in a subject in need thereof, wherein the pre-myeloid or myeloid malignancy is not chronic myeloid leukemia (CML).

traducir

ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS

NºPublicación: WO2021084063A1 06/05/2021

Solicitante:

MORPHOSYS AG [DE]

US_2021130461_A1

Resumen de: WO2021084063A1

The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (Υσ T-cells) for use in the treatment of leukemia or lymphoma.

traducir

ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA

NºPublicación: WO2021084062A1 06/05/2021

Solicitante:

MORPHOSYS AG [DE]

US_2021130460_A1

Resumen de: WO2021084062A1

The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.

traducir

ALK INHIBITORS FOR TREATMENT OF ALK-NEGATIVE CANCER AND PLASMA CELL-MEDIATED DISEASES

NºPublicación: WO2021083555A1 06/05/2021

Solicitante:

UNIV OSLO [NO]

Resumen de: WO2021083555A1

The present invention provides a method of treating ALK-negative/LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.

traducir

METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA

NºPublicación: WO2021087044A1 06/05/2021

Solicitante:

CELGENE CORP [US]

Resumen de: WO2021087044A1

Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.

traducir

METHODS FOR TREATING LEUKEMIA AND USE OF A LEUKEMIC STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPIES

NºPublicación: WO2021086829A1 06/05/2021

Solicitante:

CELGENE CORP [US]

Resumen de: WO2021086829A1

Provided herein are methods of using certain biomarkers, such as gene sets (e.g., a leukemic stem cell (LSC) signature), in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancer (e.g, lymphoma, multiple myeloma (MM), and leukemia, such as acute myeloid leukemia (AML)). Also provided herein are methods of treating diseases using the treatment compounds.

traducir

GENERATION OF CD38 KNOCK-OUT PRIMARY AND EXPANDED HUMAN NK CELLS

NºPublicación: WO2021087466A1 06/05/2021

Solicitante:

RES INST NATIONWIDE CHILDRENS HOSPITAL [US]
UNIV JOHNS HOPKINS [US]

Resumen de: WO2021087466A1

Disclosed are genetically modified NK cells comprising a knockout of the cluster of differentiation 38 (CD38) gene and methods of using the same to treat a cancer including, but not limited to multiple myeloma, acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or Blastic plasmacytoid dendritic cell neoplasm (BPDCN).

traducir

SELF-EMULSIFYING DRUG DELIVERY SYSTEM AND USES THEREOF

NºPublicación: WO2021081654A1 06/05/2021

Solicitante:

SP NUTRACEUTICALS INC [CA]

Resumen de: WO2021081654A1

A self-emulsifying drug delivery system (SEDDS) may include an avocado polyol, a surfactant, and an oil. An in vitro method of treating acute myeloid leukemia cells may include treating the cells with a therapeutically effective amount of the SEDDS.

traducir

CONJUNCTIVAL DISEASE DETECTION METHOD USING OCULAR SURFACE TISSUE, AND BIOMARKER FOR AGING

NºPublicación: EP3816300A1 05/05/2021

Solicitante:

UNIV OSAKA [JP]
OTSUKA PHARMA CO LTD [JP]

WO_2020004626_PA

Resumen de: EP3816300A1

It aims to construct a technology in which the onset or progression of an aging state or a specific disease can be evaluated in an objective and highly reproducible manner, and in particular, to provide a method of detecting conjunctival diseases such as conjunctival MALT lymphoma, and to provide an aging biomarker that serves as an indicator of the aging state.A method of detecting a conjunctival disease using an ocular surface tissue, the method comprising a step of comparing a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a healthy person, with a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a subject to detect an ocular surface tissue specimen which is sampled from the subject evaluated as having the conjunctival disease based on a change in the microbial community structure between the healthy person and the subject, and an aging biomarker for detecting an aging state, the aging biomarker comprising a bacterial species which belongs to at least one family selected from Corynebacteriaceae family and Propionibacteriales family in an ocular surface tissue.

traducir

Composition for Inhibiting or Treating for Acute Myeloid Leukemia or Metastatic Breast Cancer

NºPublicación: KR20210047850A 30/04/2021

Solicitante:

PELEMED CO LTD [KR]

Resumen de: KR20210047850A

본 발명은 인디루빈 유도체를 유효 성분으로 포함하는 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물에 관한 것이다. 본 발명의 조성물을 이용하는 경우 FLT3 키나아제의 활성을 효과적으로 억제하고, 급성 골수성 백혈병 또는 전이성 유방암을 예방 또는 치료하는데 유용하게 사용할 수 있다.

traducir

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

Nº publicación: US2021123063A1 29/04/2021

Solicitante:

US HEALTH [US]

AU_2021202158_A1

Resumen de: US2021123063A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

Página1 de 3 nextPage por página

punteroimgVolver